cyclooxygenase-2 (COX-2) specific inhibitor
Jump to navigation
Jump to search
Contraindications
- avoid in patients with cardiovascular risk factors
* safe in patients with aspirin-exacerbated respiratory disease[12]
Adverse effects
- hypertension (especially systolic hypertension)
- diminished renal function
- peripheral edema
- heart failure
- upper GI bleed (probably less-likely than non-selective NSAIDs)
Drug interactions
- as likely as non-selective NSAIDs to potential upper GI bleeding when used in combination with warfarin[8]
- drug interaction(s) of cholinesterase inhibitors with NSAIDs
- drug interaction(s) of lithium carbonate with NSAIDs
- drug interaction(s) of NSAIDs with oral contraceptive
- drug interaction(s) of NSAIDs with SSRIs
- drug interaction(s) of NSAIDs with antidepressants
- drug interaction(s) of aspirin with NSAIDs
- drug interaction(s) of apixaban with NSAIDs
- drug interaction(s) of warfarin with NSAIDs
- drug interaction(s) of NSAIDs with beta blockers
- drug interaction(s) of NSAIDs with ARBs
- drug interaction(s) of coxib with SSRI
- drug interaction(s) of NSAIDs with aldosterone antagonis
- drug interaction(s) of NSAIDs with glucocorticoid
- drug interaction(s) of NSAIDs, diuretics & angiotensin II receptor antagonists
- drug interaction(s) of NSAIDs, diuretics & ACE inhibitors
- drug interaction(s) of NSAIDs with ACE inhibitors
- drug interaction(s) of NSAIDs & antihypertensives
- drug interaction(s) of NSAIDs & loop diuretics
- drug interaction(s) of NSAIDs & aspirin
Mechanism of action
- selectively inhibit cyclo-oxygenase-2 (COX-2)
- inhibition of prostacyclin production
- do NOT inhibit platelet aggregation
Notes
December 23, 2004: The U.S. Food and Drug Administration (FDA) issued a public health advisory concerning use of non-steroidal anti-inflammatory drug products (NSAIDs) including those known as COX-2 selective agents.[5]
More general terms
More specific terms
- carprofen (Rimadyl, Imadyl, Imafen)
- celecoxib (Celebrex)
- deracoxib (Deramaxx)
- etoricoxib (Arcoxia)
- firocoxib (Equioxx, Previcox)
- lumiracoxib (Prexige)
- parecoxib (Dynastat)
- robenacoxib (Onsior)
- rofecoxib (Vioxx)
- valdecoxib (Bextra)
Additional terms
References
- ↑ Prescriber's Letter 7(10):55 2000
- ↑ Prescriber's Letter 8(6):31-32 2001
- ↑ Journal Watch 23(13):103, 2003 Spiegel BMR et al, Ann Intern Med 138:795, 2003
- ↑ Prescriber's Letter 11(11): 2004 Safety of COX-2 Inhibitors and Their Place in Therapy Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=201102&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 http://www.fda.gov/cder/drug/advisory/nsaids.htm
- ↑ Prescriber's Letter 12(2): 2005 Update on the Safety and Use of COX-2 Inhibitors and Traditional NSAIDs Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210202&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 12(3): 2005 COX-2 Inhibitor Safety: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210301&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 8.0 8.1 Journal Watch 25(6):46, 2005 Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005 Jan 24;165(2):189-92. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15668365
- ↑ Prescriber's Letter 12(5): 2005 FDA Announces Important Changes and Additional Warnings for COX-2s and NSAIDs Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210505&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA MedWatch COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#NSAID
- ↑ 11.0 11.1 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
- ↑ 12.0 12.1 12.2 Morales DR et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014 Jul; 134:40 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24388008